ID

31116

Description

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00667082

Link

https://clinicaltrials.gov/show/NCT00667082

Keywords

Versions (1)
  1. 7/21/18 7/21/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 21, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Small Cell Lung Cancer NCT00667082

English

Eligibility Non-Small Cell Lung Cancer NCT00667082

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. karnofsky performance status (kps) at 70% or more.
Description

Karnofsky Performance Status

Data type

boolean

Alias
UMLS CUI [1]
C0206065
2. non-small cell lung cancer, pancreatic adenocarcinoma, melanoma or lymphoma for which a standard, approved therapy is not available. patients must have lesions that are evaluable by recist criteria.
Description

Non-Small Cell Lung Carcinoma | Adenocarcinoma of pancreas | Standard therapy Unavailable Melanoma | Standard therapy Unavailable Lymphoma | Lesion Evaluable

Data type

boolean

Alias
UMLS CUI [1]
C0007131
UMLS CUI [2]
C0281361
UMLS CUI [3,1]
C2936643
UMLS CUI [3,2]
C0686905
UMLS CUI [3,3]
C0025202
UMLS CUI [4,1]
C2936643
UMLS CUI [4,2]
C0686905
UMLS CUI [4,3]
C0024299
UMLS CUI [5,1]
C0221198
UMLS CUI [5,2]
C1516986
3. all adverse events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to ctcae (v. 3.0) grade 1 or less(except for hemoglobin).
Description

Adverse event Due to Prior Chemotherapy | Adverse event Due to Operative Surgical Procedures | Adverse event Due to Therapeutic radiology procedure | Resolution CTCAE Grades | Exception Hemoglobin

Data type

boolean

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C1514457
UMLS CUI [2,1]
C0877248
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0543467
UMLS CUI [3,1]
C0877248
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C1522449
UMLS CUI [4,1]
C1514893
UMLS CUI [4,2]
C1516728
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0019046
4. adequate bone marrow, renal, liver function.
Description

Bone Marrow function | Renal function | Liver function

Data type

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
5. signed informed consent.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. recent administration of chemotherapy, biological, immunotherapy or investigational agent, major surgery, or radiotherapy.
Description

Chemotherapy | Biological treatment | Immunotherapy | Investigational New Drugs | Major surgery | Therapeutic radiology procedure

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1531518
UMLS CUI [3]
C0021083
UMLS CUI [4]
C0013230
UMLS CUI [5]
C0679637
UMLS CUI [6]
C1522449
2. intrathecal therapy.
Description

Intrathecal therapy

Data type

boolean

Alias
UMLS CUI [1]
C1831734
3. known brain metastases.
Description

Metastatic malignant neoplasm to brain

Data type

boolean

Alias
UMLS CUI [1]
C0220650
4. significant cardiac disease.
Description

Heart Disease

Data type

boolean

Alias
UMLS CUI [1]
C0018799
5. prior treatment with vorinostat or npi-0052, or other hdaci (including valproic acid) or proteasome inhibitors.
Description

Vorinostat | NPI 0052 | Histone deacetylase inhibitor | Valproic Acid | Proteasome inhibitors

Data type

boolean

Alias
UMLS CUI [1]
C0672708
UMLS CUI [2]
C1570638
UMLS CUI [3]
C1512474
UMLS CUI [4]
C0042291
UMLS CUI [5]
C1443643
6. known allergy to any component of vorinostat. prior hypersensitivity reaction of ctcae grade > 3 to therapy containing propylene glycol or ethanol.
Description

Hypersensitivity Vorinostat Component | Hypersensitivity CTCAE Grades Propylene glycol | Hypersensitivity CTCAE Grades Ethanol

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0672708
UMLS CUI [1,3]
C1705248
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1516728
UMLS CUI [2,3]
C0072225
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C1516728
UMLS CUI [3,3]
C0001962
7. pregnant or breast-feeding women.
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
8. concurrent, active secondary malignancy for which the patient is receiving therapy.
Description

Therapeutic procedure Secondary Malignant Neoplasm

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C3266877
9. significant active infection.
Description

Communicable Disease

Data type

boolean

Alias
UMLS CUI [1]
C0009450
Back to the top of the page

Similar models

Eligibility Non-Small Cell Lung Cancer NCT00667082

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Karnofsky Performance Status
Item
1. karnofsky performance status (kps) at 70% or more.
boolean
C0206065 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma | Adenocarcinoma of pancreas | Standard therapy Unavailable Melanoma | Standard therapy Unavailable Lymphoma | Lesion Evaluable
Item
2. non-small cell lung cancer, pancreatic adenocarcinoma, melanoma or lymphoma for which a standard, approved therapy is not available. patients must have lesions that are evaluable by recist criteria.
boolean
C0007131 (UMLS CUI [1])
C0281361 (UMLS CUI [2])
C2936643 (UMLS CUI [3,1])
C0686905 (UMLS CUI [3,2])
C0025202 (UMLS CUI [3,3])
C2936643 (UMLS CUI [4,1])
C0686905 (UMLS CUI [4,2])
C0024299 (UMLS CUI [4,3])
C0221198 (UMLS CUI [5,1])
C1516986 (UMLS CUI [5,2])
Adverse event Due to Prior Chemotherapy | Adverse event Due to Operative Surgical Procedures | Adverse event Due to Therapeutic radiology procedure | Resolution CTCAE Grades | Exception Hemoglobin
Item
3. all adverse events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to ctcae (v. 3.0) grade 1 or less(except for hemoglobin).
boolean
C0877248 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C1514457 (UMLS CUI [1,3])
C0877248 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0543467 (UMLS CUI [2,3])
C0877248 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C1522449 (UMLS CUI [3,3])
C1514893 (UMLS CUI [4,1])
C1516728 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0019046 (UMLS CUI [5,2])
Bone Marrow function | Renal function | Liver function
Item
4. adequate bone marrow, renal, liver function.
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Informed Consent
Item
5. signed informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Chemotherapy | Biological treatment | Immunotherapy | Investigational New Drugs | Major surgery | Therapeutic radiology procedure
Item
1. recent administration of chemotherapy, biological, immunotherapy or investigational agent, major surgery, or radiotherapy.
boolean
C0392920 (UMLS CUI [1])
C1531518 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
C0679637 (UMLS CUI [5])
C1522449 (UMLS CUI [6])
Intrathecal therapy
Item
2. intrathecal therapy.
boolean
C1831734 (UMLS CUI [1])
Metastatic malignant neoplasm to brain
Item
3. known brain metastases.
boolean
C0220650 (UMLS CUI [1])
Heart Disease
Item
4. significant cardiac disease.
boolean
C0018799 (UMLS CUI [1])
Vorinostat | NPI 0052 | Histone deacetylase inhibitor | Valproic Acid | Proteasome inhibitors
Item
5. prior treatment with vorinostat or npi-0052, or other hdaci (including valproic acid) or proteasome inhibitors.
boolean
C0672708 (UMLS CUI [1])
C1570638 (UMLS CUI [2])
C1512474 (UMLS CUI [3])
C0042291 (UMLS CUI [4])
C1443643 (UMLS CUI [5])
Hypersensitivity Vorinostat Component | Hypersensitivity CTCAE Grades Propylene glycol | Hypersensitivity CTCAE Grades Ethanol
Item
6. known allergy to any component of vorinostat. prior hypersensitivity reaction of ctcae grade > 3 to therapy containing propylene glycol or ethanol.
boolean
C0020517 (UMLS CUI [1,1])
C0672708 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C1516728 (UMLS CUI [2,2])
C0072225 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C1516728 (UMLS CUI [3,2])
C0001962 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
7. pregnant or breast-feeding women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Therapeutic procedure Secondary Malignant Neoplasm
Item
8. concurrent, active secondary malignancy for which the patient is receiving therapy.
boolean
C0087111 (UMLS CUI [1,1])
C3266877 (UMLS CUI [1,2])
Communicable Disease
Item
9. significant active infection.
boolean
C0009450 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial